Literature DB >> 30254105

Increased acute care utilization in a prospective cohort of adults with sickle cell disease.

Sophie Lanzkron1, Jane Little2, Joshua Field3, Joseph Ryan Shows4, Hang Wang1, Rebecca Seufert1, Jasmine Brooks1, Ravi Varadhan5, Carlton Haywood1, Mustapha Saheed6, Chiung Yu Huang7, Brandi Griffin2, Steven Frymark3, Allie Piehet4, Derek Robertson1, Marc Proudford1, Adrienne Kincaid2, Charles Green3, Lorri Burgess4, Marcus Wallace8, Jodi Segal1.   

Abstract

The ESCAPED (Examining Sickle Cell Acute Pain in the Emergency vs Day Hospital) trial is an ongoing prospective study comparing outcomes of people with sickle cell disease (SCD) seeking care for acute pain management in either an emergency department or specialty infusion clinic. The objective of this paper is to describe the baseline characteristics and health care utilization of patients in the trial. This is a multicenter study across 4 US cities that enrolled all adults with SCD living within 60 miles (96.6 km) of a study site who were expected to have acute care utilization over the study period. Twenty-one percent of participants had no acute care visits in the first 12 months of follow-up. Using negative binomial regression, we describe subject characteristics that predict acute care utilization. Three hundred ninety-one subjects have completed 12 months of follow-up with a mean age of 34.5 years (standard deviation, 11.4), 60% are female. Fifty-four percent of subjects with hemoglobin SS disease and 46% with hemoglobin SC disease had 3 or more acute visits over the study period. The prevalence of chronic pain in this cohort was 68%. Predictors of higher rates of acute care utilization included being unemployed, having chronic pain, being on chronic transfusion therapy, having a history of stroke, and being on disability or on Medicaid. This is the first prospective cohort in the modern era, and it demonstrates much higher rates of acute care utilization than reported in the Cooperative Study of Sickle Cell Disease.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 30254105      PMCID: PMC6156885          DOI: 10.1182/bloodadvances.2018018382

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  17 in total

1.  Day case management of sickle pain: 3 years experience in a UK sickle cell unit.

Authors:  J Wright; D Bareford; C Wright; G Augustine; K Olley; L Musamadi; C Dhanda; C Knight
Journal:  Br J Haematol       Date:  2004-09       Impact factor: 6.998

2.  Effectiveness of a dedicated day hospital for management of acute sickle cell pain.

Authors:  Adeboye H Adewoye; Vikki Nolan; Lillian McMahon; Qianli Ma; Martin H Steinberg
Journal:  Haematologica       Date:  2007-06       Impact factor: 9.941

3.  Day hospital versus inpatient management: An economic initiative of a pediatric center, examplified on uncomplicated vaso-occlusive crises of children with sickle cell disease.

Authors:  Paul Imbach
Journal:  Pediatr Blood Cancer       Date:  2008-09       Impact factor: 3.167

4.  Impact of a dedicated infusion clinic for acute management of adults with sickle cell pain crisis.

Authors:  Sophie Lanzkron; C Patrick Carroll; Peter Hill; Mandy David; Nicklaine Paul; Carlton Haywood
Journal:  Am J Hematol       Date:  2015-02-25       Impact factor: 10.047

5.  AAPT Diagnostic Criteria for Chronic Sickle Cell Disease Pain.

Authors:  Carlton Dampier; Tonya M Palermo; Deepika S Darbari; Kathryn Hassell; Wally Smith; William Zempsky
Journal:  J Pain       Date:  2017-01-05       Impact factor: 5.820

6.  Risky behavior in teens with cystic fibrosis or sickle cell disease: a multicenter study.

Authors:  M T Britto; J M Garrett; M A Dugliss; C W Daeschner; C A Johnson; M W Leigh; J M Majure; W H Schultz; T R Konrad
Journal:  Pediatrics       Date:  1998-02       Impact factor: 7.124

7.  Treatment of uncomplicated vaso-occlusive crises in children with sickle cell disease in a day hospital.

Authors:  Jean L Raphael; Aditi Kamdar; M Brooke Beavers; Donald H Mahoney; Brigitta U Mueller
Journal:  Pediatr Blood Cancer       Date:  2008-07       Impact factor: 3.167

8.  Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void.

Authors:  Lawrence R Solomon
Journal:  Blood       Date:  2007-10-16       Impact factor: 22.113

9.  Daily assessment of pain in adults with sickle cell disease.

Authors:  Wally R Smith; Lynne T Penberthy; Viktor E Bovbjerg; Donna K McClish; John D Roberts; Bassam Dahman; Imoigele P Aisiku; James L Levenson; Susan D Roseff
Journal:  Ann Intern Med       Date:  2008-01-15       Impact factor: 25.391

10.  Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.

Authors:  Sherif M Badawy; Alexis A Thompson; Jin-Shei Lai; Frank J Penedo; Karen Rychlik; Robert I Liem
Journal:  Health Qual Life Outcomes       Date:  2017-07-05       Impact factor: 3.186

View more
  12 in total

1.  Development of a Severity Classification System for Sickle Cell Disease.

Authors:  Nirmish Shah; David Beenhouwer; Michael S Broder; Lanetta Bronte-Hall; Laura M De Castro; Sarah N Gibbs; Victor R Gordeuk; Julie Kanter; Elizabeth S Klings; Thokozeni Lipato; Deepa Manwani; Brigid Scullin; Irina Yermilov; Wally R Smith
Journal:  Clinicoecon Outcomes Res       Date:  2020-10-28

Review 2.  A Comprehensive Review of the Treatment and Management of Pain in Sickle Cell Disease.

Authors:  Jacob Fiocchi; Ivan Urits; Vwaire Orhurhu; Mariam Salisu Orhurhu; Stephen Giacomazzi; Briggs Hoyt; Alan D Kaye; Rachel J Kaye; Omar Viswanath
Journal:  Curr Pain Headache Rep       Date:  2020-03-21

3.  Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.

Authors:  Nancy Crego; Christian Douglas; Emily Bonnabeau; Marian Earls; Kern Eason; Elizabeth Merwin; Gary Rains; Paula Tanabe; Nirmish Shah
Journal:  J Am Board Fam Med       Date:  2020 Jan-Feb       Impact factor: 2.657

4.  Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects.

Authors:  Julie Kanter; Wally R Smith; Payal C Desai; Marsha Treadwell; Biree Andemariam; Jane Little; Diane Nugent; Susan Claster; Deepa G Manwani; Judith Baker; John J Strouse; Ifeyinwa Osunkwo; Rosalyn W Stewart; Allison King; Lisa M Shook; John D Roberts; Sophie Lanzkron
Journal:  Blood Adv       Date:  2020-08-25

5.  Cognitive performance as a predictor of healthcare transition in sickle cell disease.

Authors:  Anjelica C Saulsberry-Abate; Marita Partanen; Jerlym S Porter; Pradeep S B Podila; Jason R Hodges; Allison A King; Winfred C Wang; Jane E Schreiber; Xiwen Zhao; Guolian Kang; Lisa M Jacola; Jane S Hankins
Journal:  Br J Haematol       Date:  2021-02-11       Impact factor: 6.998

6.  Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease.

Authors:  Santosh L Saraf; Krishna Ghimire; Pritesh Patel; Karen Sweiss; Michel Gowhari; Robert E Molokie; Victor R Gordeuk; Damiano Rondelli
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

7.  Severe Persistent Pain and Inflammatory Biomarkers in Sickle Cell Disease: An Exploratory Study.

Authors:  Mitchell R Knisely; Paula J Tanabe; Julia K L Walker; Qing Yang; Nirmish R Shah
Journal:  Biol Res Nurs       Date:  2021-06-30       Impact factor: 2.318

8.  Emergency Department Utilization for Patients Living With Sickle Cell Disease: Psychosocial Predictors of Health Care Behaviors.

Authors:  Khadijah Abdallah; Ashley Buscetta; Kayla Cooper; Julia Byeon; Andrew Crouch; Sabrina Pink; Caterina Minniti; Vence L Bonham
Journal:  Ann Emerg Med       Date:  2020-09       Impact factor: 5.721

9.  Beta2-Adrenergic Receptor Polymorphisms and Haplotypes Associate With Chronic Pain in Sickle Cell Disease.

Authors:  Ellie H Jhun; Nilanjana Sadhu; Xiaoyu Hu; Yingwei Yao; Ying He; Diana J Wilkie; Robert E Molokie; Zaijie Jim Wang
Journal:  Front Pharmacol       Date:  2019-02-07       Impact factor: 5.810

Review 10.  Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease.

Authors:  Santosh L Saraf; Damiano Rondelli
Journal:  J Clin Med       Date:  2019-10-01       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.